Abstract
Pancreatic cancer is one of the most lethal neoplasms and only 5% of affected individuals survive more than 5 years after diagnosis, with ductal adenocarcinoma (PDAC) being the most prevalent and aggressive type. Chemotherapy with gemcitabine is the standard treatment protocol for invasive PDAC and is also used as adjuvant therapy after surgical removal of the tumor. However, the clinical…